Allogene Therapeutics, Inc. (ALLO) Return on equity 2019–2025
Allogene Therapeutics, Inc. (ALLO) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-65.3%FY2025 · since FY2019: -29.3% → -65.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -65.3% | -4.2 pp |
| FY2024 | -61.0% | +2.9 pp |
| FY2023 | -63.9% | -12.8 pp |
| FY2022 | -51.0% | -31.4 pp |
| FY2021 | -19.7% | +11.5 pp |
| FY2020 | -31.2% | -1.9 pp |
| FY2019 | -29.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More ALLO financial trends
ALLO RevenueALLO Net incomeALLO Net marginALLO Gross profitALLO Gross marginALLO Operating incomeALLO Operating marginALLO Operating cash flowALLO Free cash flowALLO Capital expendituresALLO Stock buybacksALLO Dividends paidALLO Total assetsALLO Total liabilitiesALLO Shareholders’ equityALLO overview →